Avidity Biosciences, Inc. (RNA) Stock

Avidity Biosciences, Inc. (RNA) is a Healthcare stock trading at $13.23 (as of 2026-08-21), with a market capitalization of $226.39M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Avidity Biosciences, Inc. is a biopharmaceutical company developing oligonucleotide-based therapies, including antibody oligonucleotide conjugates intended for diseases such as myotonic dystrophy type 1 and Duchenne muscular dystrophy, with additional candidates in earlier-stage development. The company also develops a treatment option for Pompe disease.

Understand Avidity Biosciences, Inc.: how it makes money

Avidity Biosciences develops oligonucleotide-based biopharmaceutical therapies, including antibody oligonucleotide conjugates (AOC) for conditions such as myotonic dystrophy type 1 (AOC 1001) and Duchenne Muscular Dystrophy (AOC 1044), plus other AOC programs in preclinical stage, and it also offers Lumizyme therapy for Pompe diseases.

The profit engine is tied to the clinical and regulatory success of its AOC platform and disease-specific lead programs (AOC 1001, AOC 1044, and preclinical AOC 1020), plus the commercial contribution from Lumizyme, with ongoing development costs pressuring profitability while programs advance.

Business quality (Weak): Limited provided detail on reportable segments and investor operating KPIs, so the analysis focuses on the publicly described therapy pipeline and the companys current profitability profile (operating margin provided).

Bull case

  • Differentiated modality and pipeline focus: The company develops oligonucleotide-based therapies, including AOC treatments aimed at serious diseases, with multiple disease programs identified (AOC 1001 and AOC 1044) and additional AOC work in preclinical stage (AOC 1020).
  • Multiple disease franchises: It has lead candidates tied to different neuromuscular diseases and also offers Lumizyme for Pompe diseases, which can diversify clinical and commercial pathways.

Bear case

  • Preclinical and execution risk: At least one key AOC program (AOC 1020) is described as preclinical, and the value of pipeline programs depends on successful progression through development.
  • Currently weak operating profitability in the provided quarter: In the period ended 2026-03-31, the company shows an operating margin of -88.0%, which indicates substantial operating pressure consistent with biotech development costs (based on the limited financial inputs provided).
Valuation — source: SEC EDGAR (first-party)
Price$13.23
Market Cap$226.39M
Price / Book1.06
Price / Sales4.14
FCF Yield-261.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$18.75M
Net Margin-3650.4%
Revenue Growth (YoY)-21.9%
EPS Growth (YoY)57.3%
FCF Growth (YoY)59.8%
Financial Health — source: SEC EDGAR
Altman Z-Score0.24 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderDecagon Asset Management LLP ($17.49B)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOSarah Boyce
Employees391
CountryUS
IPO Date2020-06-12

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Whitehawk Therapeutics Inc (WHWK)
  • Organogenesis Holdings Inc. (ORGO)
  • Minerva Neurosciences, Inc. (NERV)
  • Immunic, Inc. (IMUX)
  • Keros Therapeutics, Inc. (KROS)
  • AN2 Therapeutics, Inc. (ANTX)
  • SIGA Technologies, Inc. (SIGA)
  • PepGen Inc. (PEPG)
RNA earnings history · RNA institutional & insider holders · RNA KPIs & operating metrics · RNA financials · RNA investor presentations & press releases · RNA SEC filings · RNA peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.